Berisha T, Postolache A, Vrancken L, et al.About a “false-positive” case of elevated troponin levels: differential diagnosis. Acta Cardiol. 2025;80(7):753–755. doi: 10.1080/00015385.2025.2462438.
Verhenne K, De Meester P, Schuurmans G, et al.Volume challenge in women with congenital heart disease during reproductive age and pregnancy outcomes. Acta Cardiol. 2025;80(7):695–702. doi: 10.1080/00015385.2025.2480939.
Lancellotti P, Budts W, Vachiery JL., Echocardiographic practices in pulmonary hypertension: survey results and literature review. Acta Cardiol. 2025;80(7):756–759. doi: 10.1080/00015385.2025.2518645
Gerber BL, Mande IK, Rizzi S, et al.30-year trends in incidence of acute STEMI and NSTEMI in the Belgian Province of Luxembourg. A long-term follow-up of the MONICA-BELLUX registry. Acta Cardiol. 2025;80(7):709–720. doi: 10.1080/00015385.2025.2524233
Quisi A, Nacar Quisi NS, Alıcı G, et al.Effect of dapagliflozin on the no-reflow phenomenon in patients with acute myocardial infarction and type iI diabetes mellitus. Acta Cardiol. 2025;80(4):394–402. doi: 10.1080/00015385.2025.2500892.
Lurquin FO, Petit EL, Ahn SA, et al.Cross-prevalence of large and small vessels disease in T2DM: overview from a Belgian academic centre. Acta Cardiol. 2025;80(7):721–729. doi: 10.1080/00015385.2025.2524239.
Jin H, Wang T., Impact of chronic kidney disease on the association of high ankle-brachial index with cardiovascular mortality and all-cause mortality. Acta Cardiol. 2025;80(7):736–744. doi: 10.1080/00015385.2025.2538405.
Meyten N, Moreels TG., How important is the risk of medical malpractice litigations against cardiologists in Belgium?Acta Cardiol. 2025;80(7):703–708. doi: 10.1080/00015385.2025.2516943.
Tanriverdi O, Askin L., Association of high-sensitivity troponin T with left ventricular dysfunction in prediabetes. Acta Cardiol. 2024;79(6):699–704. doi: 10.1080/00015385.2024.2365605.
Van Assche L, Peeters B, Vorlat A, et al.Safety and effectiveness of the short (0-1h) high sensitive troponin protocol in real-life practice. Acta Cardiol. 2023;78(8):937–944. doi: 10.1080/00015385.2023.2218028.
Papageorgiou N, Sohrabi C, Prieto Merino D, et al.High sensitivity troponin and COVID-19 outcomes. Acta Cardiol. 2022;77(1):81–88. doi: 10.1080/00015385.2021.1887586.
Seghaye MC., Volume challenge in women with congenital heart disease during reproductive age and pregnancy outcome’ by K. VERHENNE et al. Acta Cardiol. 2025;5:1–2.
Vachiéry JL, Belge C, Cools B, et al.A Belgian consensus on sotatercept for the treatment of pulmonary arterial hypertension. Acta Cardiol. 2024;79(9):978–983. doi: 10.1080/00015385.2024.2408130.
Lancellotti P, Dulgheru R., Advancing strategies for valvular heart disease and pulmonary hypertension: insights and perspectives. Acta Cardiol. 2024;79(9):973–977. doi: 10.1080/00015385.2024.2436769.
Behrooz L, Barillas-Lara M, Fattouh M, et al. The role of invasive cardiopulmonary exercise testing in patients with unexplained dyspnea: a systemic review. Acta Cardiol. 2023;78:754–760.
Minten L, Dubois C, Desmet W, et al.Economical aspects of coronary angiography for diagnostic purposes: a Belgian perspective. Acta Cardiol. 2024;79(1):41–45. doi: 10.1080/00015385.2023.2281105.
Ungureanu C, Mirica DC, Marcovitch O, et al.Dobutamine stress echocardiography in patients with moderate coronary artery disease detected by coronary computed tomography angiography could reduce the rate of unnecessary coronary angiography. Acta Cardiol. 2022;77(7):602–608. doi: 10.1080/00015385.2021.1968154.
Zhou Y, Lu D, Hu Y, et al.Coronary slow flow and angiography-derived index of microcirculatory resistance as prognostic predictors in patients with angina and normal coronary arteries: a retrospective cohort study. Acta Cardiol. 2024;79(2):149–158. doi: 10.1080/00015385.2023.2281115.
Seydel GS, Gunturk I, Akkaya H, et al.The relationship between the new inflammatory markers and disease severity in patients with acute coronary syndrome. Acta Cardiol. 2024;79(7):778–786. doi: 10.1080/00015385.2024.2403933.
Almeida I, Chin J, Santos H, et al.Revascularization strategies in STEMI and multivessel disease. Acta Cardiol. 2023;78(1):32–39. doi: 10.1080/00015385.2021.1999570.
Claeys MJ., Reperfusion injury in STEMI patients: another piece of the puzzle. Acta Cardiol. 2023;78(1):162–163. doi: 10.1080/00015385.2022.2027636.
Sonsöz MR, Şişman A, Güler A., What lies behind the extensive ST-segment changes in cardiac arrest?Acta Cardiol. 2023;78(8):968–969. doi: 10.1080/00015385.2023.2243062.
Esenboğa K, Kurtul A, Yamantürk YY, et al.Systemic immune-inflammation index predicts no-reflow phenomenon after primary percutaneous coronary intervention. Acta Cardiol. 2022;77(1):59–65. doi: 10.1080/00015385.2021.1884786.
Jain A, Desai R, Shenwai P, et al.Impact of D-dimer levels on no-reflow phenomenon following percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. Acta Cardiol. 2023;78(8):970–973. doi: 10.1080/00015385.2022.2097346.
Toprak K, Kaplangoray M, Akyol S, et al.The non-HDL-C/HDL-C ratio is a strong and independent predictor of the no-reflow phenomenon in patients with ST-elevation myocardial infarction. Acta Cardiol. 2024;79(2):194–205. doi: 10.1080/00015385.2023.2299102.
Kalyoncuoglu M, Gumusdag A, Oguz H, et al.Newly defined biomarker for the no reflow phenomenon in patients with non-ST elevation acute coronary syndrome; uric acid to creatinine ratio. Acta Cardiol. 2025;80(1):61–69. doi: 10.1080/00015385.2025.2452101.
Iacoviello M, Marini M, Gori M, et al.DAPA-HF applicability: the point of view of a cardiology setting. Acta Cardiol. 2023;78(7):840–845. doi: 10.1080/00015385.2023.2243130.
Davidsen C., Commentary on Effect of dapagliflozin on the no-reflow phenomenon in patients with acute myocardial infarction and type iI diabetes mellitus. Acta Cardiol. 2025;80(7):762–763. doi: 10.1080/00015385.2025.2524238.
Du P, Jiang J, Liu Y, et al.Correlation between vascular endothelial function and bone mineral density in type 2 diabetes mellitus patients with MAFLD. Acta Cardiol. 2025;80(1):30–38. doi: 10.1080/00015385.2024.2436813.
Boulmpou A, Patoulias D, Papadopoulos CE, et al.Meta-analysis of cardiovascular outcome trials assessing the impact of glucagon-like peptide-1 receptor agonists on major cardiac arrhythmias. Acta Cardiol. 2023;78(5):519–524. doi: 10.1080/00015385.2022.2087839.
Afshani MR, Torfi E, Akiash N, et al.Effect of empagliflozin on left ventricular volumes in type 2 diabetes or prediabetes heart failure patients with reduced ejection fraction. Acta Cardiol. 2024;79(4):419–425. doi: 10.1080/00015385.2023.2240130.
Dhont S, Singh A, Swinnen B, et al.Empagliflozin in heart failure with preserved ejection fraction: from randomized trials to real-world evidence. Acta Cardiol. 2025;80(7):730–735. doi: 10.1080/00015385.2025.2538386.
Zhou Y, Wang FR, Wen FF, et al.The association between sodium/glucose cotransporter-2 inhibitors and adverse clinical events in patients with chronic kidney disease: a systematic review and meta-analysis of randomised controlled trials. Acta Cardiol. 2024;79(3):274–283. doi: 10.1080/00015385.2023.2250949.
Jouret F, Huart J., Comments on: AC-2025-00245R2. Impact of chronic kidney disease on the association of high ankle brachial index with cardiovascular mortality and all-cause mortality. Acta Cardiol. 2025;80(7):764–765. doi: 10.1080/00015385.2025.2544369.
Henry JP, Luchian ML, Gabriel L, et al.Left ventricular compression from giant emphysematous bulla. Acta Cardiol. 2025;80(7):745–746. doi: 10.1080/00015385.2025.2450954.
